Asymmetric 1,4-additions of gilman reagents to α,β - disubstitoted (e)-enoylsultams / “enolate” protonations
作者:Wolfgang Oppolzer、Arend J. Kingma、Giovanni Poli
DOI:10.1016/0040-4020(89)80075-4
日期:1989.1
Successive treatment of (E)-Cα,Cβ-disubstltuted N-enoyl sultams 6 and 13 with organocopper reagents (Me2CuLi, (CH2CH)2CuLi, Ph2CuLi in the presence of PBu3 or SCN−) and aq. NH4Cl gave products 7 and 14. respectivety, with good to excellent stereoface differentiation at Cβ and Cα. Crystallization and mild saponification 7 → 11 and 14 → 15 furnished enantiomerically pure carboxylic acids containing
Homocereulide, isolated from marine bacterium Bacillus cereus, is an analog of emetictoxincereulide. There is no report on its structure determination and involvement in B. cereus-associated food poisoning. Homocereulide is a cyclic dodecadepsipeptide composed of l-O-Val-l-Val-d-O-Leu-d-Ala and l-O-allo-Ile-d-Val-d-O-Leu-d-Ala. Here, we synthesized homocereulide using liquid phase fragment condensation
申请人:National University Corporation
Tokyo University Of Agriculture and Technology
公开号:EP2452679A1
公开(公告)日:2012-05-16
Disclosed is a cytoprotective agent for use with respect to ischemic damage, including as an active ingredient a triprenyl phenol compound represented by the following general formula (I), wherein X is -CHY-C(CH3)2Z, Y and Z are each independently -H or -OH, or jointly form a single bond, and R represents a hydrogen atom or a substituent with a molecular weight of 1000 or less.
公开了一种用于缺血性损伤的细胞保护剂,包括作为活性成分的由以下通式(I)代表的三烯丙基酚化合物,其中 X 为-CHY-C(CH3)2Z,Y 和 Z 各自独立地为-H 或-OH,或共同形成单键,R 代表氢原子或分子量为 1000 或以下的取代基。
US8466291B2
申请人:——
公开号:US8466291B2
公开(公告)日:2013-06-18
[EN] NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION<br/>[FR] NOUVELLES HÉTEROARYLDIHYDROPYRIMIDINES CONDENSÉES EN POSITION 6 POUR LE TRAITEMENT ET LA PROPHYLAXIE D'UNE INFECTION À VIRUS DE L'HÉPATITE B
申请人:HOFFMANN LA ROCHE
公开号:WO2015132276A1
公开(公告)日:2015-09-11
The invention provides novel compounds having the general formula (I): wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds. These compounds useful for therapy and/or prophylaxis in a human, and in particular to Hepatitis B virus (HBV) inhibitors by targeting on HBV capsid for the treatment of HBV infection.